4DMedical (ASX:4DX) - Founder & CEO, Andreas Fouras
Founder & CEO, Andreas Fouras
Source: 4DMedical
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • 4DMedical (4DX) prepares sell one of its preclinical respiratory scanners to the University of Michigan in the US
  • 4DX’s Permetium preclinical scanner will be used to perform lung function imaging and vascular changes at the university’s Institute of Health
  • The scanner sale is valued at US$600,000 (approximately A$786,967) and is set to be shipped in the coming months
  • 4DMedical shares are up 2.76 per cent and trading at $1.31

4DMedical (4DX) is set to sell one of its preclinical respiratory scanners to the University of Michigan in the US.

4DX’s Permetium preclinical scanner will be installed and used at the university in its Center for Molecular Imaging to perform imaging of lung function and vascular changes.

The sale is valued at US$600,000 (approximately A$786,967) and will be funded by the Institutes of Health (NIH), a biomedical and public health research government agency in the US.

Additionally, the sale price includes the use of 4DMedical’s software to analyse respiratory scans generated from the preclinical scanner, with additional scans hoped to generate software-as-a-service (SaaS) revenue.

The scanner is primarily used for cardiothoracic translational research — concerning the heart, lungs esophagus and other chest organs — and to evaluate novel classes of drugs for cardiothoracic diseases.

4DMedical Founder and Chief Executive Officer Andreas Fouras said he was pleased to support the university.

“This provides the organisation with the only commercially available device for ultra-highresolution imaging and quantification of cardiothoracic disease models,” he said.

“The sale of preclinical scanners and XV Technology software to opinion-leading sites will provide further evidence of the effectiveness of our technology and help drive clinical demand for 4DMedical’s software products.”

The scanner is expected to be shipped to the University of Michigan within the coming months.

4DMedical shares were up 2.76 per cent and trading at $1.31 at 11:35 am AEST.

4DX by the numbers
More From The Market Herald
The Market Herald Video

" Next Science’s (ASX:NXS) CEO submits resignation

Next Science’s (ASX:NXS) CEO has announced her intention to retire before June 30, 2023.
The Market Herald Video

" Race Oncology (ASX:RAC) completes first-phase Zantrene leukaemia trial

Cancer treatment company Race Oncology (ASX:RAC) has completed the latest stage of its first-phase trial for…
The Market Herald Video

" Immutep (ASX:IMM) publishes “favourable” interim data from second-phase efti trial

Immutep (ASX:IMM) has published new interim data from Part A of its second-phase TACTI-002 trial showing…

" Microba Life Sciences (ASX:MAP) partners with Midnight Health

Microba Life Sciences (ASX:MAP) has signed a strategic partnership agreement with healthcare company, Midnight Health, to…